Nantes, France – April 2, 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the publication of novel data in the peer-reviewed Journal of Immunology (1) ...
Researchers discover ABCA1 protein’s role in releasing molecular brakes on solid tumor immunotherapy
In recent years, cancer researchers have made major breakthroughs by using the body’s immune system to fight cancer. One of the most promising approaches, known as immune checkpoint blockade, works by ...
Immune checkpoint blockade (ICB) targeting T cells has enhanced clinical outcomes in patients with renal and bladder cancers; however, response rates remain limited, particularly in cases of ...
The 2026 PSMA and Beyond conference featured an approaches to combination therapies session and presentation by Dr. Lawrence ...
In recent years, cancer researchers have made major breakthroughs by using the body's immune system to fight cancer. One of the most promising approaches, known as immune checkpoint blockade, works by ...
Tumor immunotherapy has become a standard of care for treating various cancers, with immune checkpoint inhibitors targeting the PD-L1/PD-1 axis proving particularly effective. While PD-L1 expression ...
Treatment paradigms remain unclear for immune-related adverse events associated with cancer checkpoint inhibitor therapies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results